These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1381 related items for PubMed ID: 16818707

  • 1. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 2. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
    Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB.
    Prostate; 2003 Oct 01; 57(2):134-9. PubMed ID: 12949937
    [Abstract] [Full Text] [Related]

  • 8. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M.
    J Urol; 2008 Jul 01; 180(1):367-72. PubMed ID: 18499161
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN, Schröder FH.
    BJU Int; 2009 Nov 01; 104(9):1191-7. PubMed ID: 19624596
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 12. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R.
    Prostate; 2006 Nov 01; 66(15):1674-85. PubMed ID: 16927304
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A, Morrissey C, O'Keane C, Mulligan N, Watson C, Smith J, Fitzpatrick JM, Watson RW.
    Cancer; 2006 Jun 15; 106(12):2743-52. PubMed ID: 16703599
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL.
    PLoS One; 2012 Jun 15; 7(1):e29068. PubMed ID: 22242155
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
    Makridakis N, Reichardt JK.
    J Mol Endocrinol; 2005 Jun 15; 34(3):617-23. PubMed ID: 15956333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.